Skip to main content

First Tracks Biotherapeutics, Inc.

corporate_fare Company Profile

First Tracks Biotherapeutics, Inc.

TRAX·NASDAQ·Life Sciences·CIK 0002091349

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company that develops immunology therapeutics for autoimmune and inflammatory diseases. The company operates in the United States and is based in San Diego, California. Its product pipeline includes ANB033, a novel anti-CD122 antagonist designed to target the shared beta subunit of the IL-15 and IL-2 receptors. Another key product is Rosnilimab, an antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues. Additionally, First Tracks Biotherapeutics, Inc. is developing ANB101, a BDCA2-modulating antibody specifically designed to target plasmacytoid dendritic cells (pDCs). The company was founded in 2019 and was formerly known as Biopharma Co., Inc. before changing its name to First Tracks Biotherapeutics, Inc. in February 2026.

First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for TRAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for TRAX spans 8-K, 424B3, 10-Q, S-1.

Recent high-impact activity:

  • Q3 Net Loss Narrows to $31.4M as First Tracks Lays Out 2027 Data Calendar
  • First Tracks Raises $200M in Private Placement at $32.75/Share
  • First Tracks Raises $200M at $32.75/Share, a 6% Discount to Last Close
  • ANB033 Hits All Endpoints in Celiac Trial, First-Ever Symptom and Histology Win
  • First Tracks Q2: FDA Fast Track for ANB033, Cash Runway Extended to Q2 2028

Short Interest & Short Volume

6.52 days to cover

FINRA reported short interest of 5,056,413 shares in TRAX as of the October 30, 2026 settlement, a 27.3% decrease from the prior period — about 6.5 days to cover at its recent average daily volume. On November 20, 2026, 53.0% of TRAX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,056,413 shares as of October 30, 2026
Change vs prior period▼ 27.3%
Days to cover6.52 at avg daily volume of 775,067
Daily short volume (FINRA facilities)53.0% of 187,558 shares on November 20, 2026
5-day average short volume51.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for TRAX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-15.

1 shelf registration

Private Placement of 6.1M Shares · Dilution of About 17%

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with T →
$40.7 -2.26% today
52-week range · as of 2026-10-15 $14.72 – $49.91
Market cap
$1.75B
Volume
504.4K (0.5× avg)
3-mo avg 951.1K
Live data · 2026-11-22 07:09 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed TRAX - Latest Insights

TRAX
Nov 03, 2026, 4:15 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $46.34
Real-time Price: $40.70 info
Change: -$5.64 (-12%) info
Market Cap: $1.75B info
TRAX
Oct 15, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.50
Real-time Price: $40.70 info
Change: +$4.20 (+12%) info
Market Cap: $1.75B info
TRAX
Oct 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $34.98
Real-time Price: $40.70 info
Change: +$5.72 (+16%) info
Market Cap: $1.75B info
TRAX
Oct 12, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.49
Real-time Price: $40.70 info
Change: +$4.21 (+12%) info
Market Cap: $1.75B info
TRAX
Aug 12, 2026, 4:19 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $45.75
Real-time Price: $40.70 info
Change: -$5.05 (-11%) info
Market Cap: $1.75B info
TRAX
Aug 12, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $45.75
Real-time Price: $40.70 info
Change: -$5.05 (-11%) info
Market Cap: $1.75B info
TRAX
May 15, 2026, 4:06 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $14.00
Real-time Price: $40.70 info
Change: +$26.70 (+191%) info
Market Cap: $1.75B info
TRAX
May 14, 2026, 4:32 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $40.70 info
Change: +$22.54 (+124%) info
Market Cap: $1.75B info
TRAX
May 14, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.16
Real-time Price: $40.70 info
Change: +$22.54 (+124%) info
Market Cap: $1.75B info
TRAX
May 08, 2026, 4:37 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $16.97
Real-time Price: $40.70 info
Change: +$23.73 (+140%) info
Market Cap: $1.75B info
TRAX
Apr 20, 2026, 5:23 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $19.59
Real-time Price: $40.70 info
Change: +$21.11 (+108%) info
Market Cap: $1.75B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets